Brain-imaging feature story about research using network-based scans to assess a synapse-targeting oral therapy and its implications for personalized Alzheimer’s care.
Key Takeaways
- Race against Alzheimer’s disease has largely revolved around amyloid plaques
- Latest generation of FDA-approved drugs aims to clear these sticky protein deposits from the brain
- New findings presented at the Alzheimer’s Association International Conference (AAIC)